NDAINTRAVENOUSSOLUTION
Approved
Sep 2023
Lifecycle
Growth
Competitive Pressure
0/100
Mechanism of Action
12.1 Mechanism of Action Micafungin is a member of the echinocandin class of antifungal agents []. 12.2 Pharmacodynamics The pharmacodynamics of micafungin related to hematogenous Candida meningoencephalitis are described in other sections of the prescribing information [ and ]. 12.3…
Indications (8)
Acute Disseminated CandidiasisAbscesses in adultolder for whom appropriate dosing with this formulation can be achieved [Abscesses without meningoencephalitis and/or ocular dissemination in pediatric patients younger than 4 months of age for whom appropriate dosing with this formulation can be achieved []Esophageal Candidiasis in adultolder for whom appropriate dosing with this formulation can be achieved []older for whom appropriate dosing with this formulation can be achievedAbscesses without meningoencephalitis and/or ocular dissemination in pediatric patients younger than 4 months of age for whom appropriate dosing with this formulation can be achieved
Loss of Exclusivity
LOE Date
Dec 15, 2037
143 months away
Patent Expiry
Dec 15, 2037
Patent Records (1)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 12403173 | Dec 15, 2037 | Product | — |
Company
B
Baxter
Costa Rica - Cartago